Controlled Release from Porous Platforms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Controlled Release from Porous Platforms


Pharmaceutical Technology Europe
Volume 23, Issue 8

By Spomenka Simovic, Dusan Losic and Krasimir Vasilev

The authors present a method for controlling the release of therapeutics by applying a plasma polymer layer to the surface of porous materials. The current study applied this technique to the release of antibiotics and a protein. The approach substantially reduced the initial burst release and provided zero-order release kinetics. The method can be applied to any type of porous drug carrier because the techniques for depositing a polymer overlayer are independent of the substrate.

This article was also published in our US sister publication Pharmaceutical Technology and can be read here.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here